0
ARTICLE |

Drug Therapy of Hyperlipoproteinemia FREE

Robert I. Levy, MD
[+] Author Affiliations

Reprint requests to National Heart and Lung Institute, Bethesda, MD 20014 (Dr Levy).


JAMA. 1976;235(21):2334-2336. doi:10.1001/jama.1976.03260470052032
Text Size: A A A
Published online

MANAGEMENT of hyperlipoproteinemia has been advanced considerably in recent years through new insights into lipid and lipoprotein metabolism, as well as into the mode of action of hypolipidemic drugs.1 A variety of highly effective lipid levellowering drugs is now available.2 Because of the heterogeneity of the hyperlipoproteinemias, no single drug is useful in all the disorders. We now know that elevated lipid levels are the result of increased production or decreased removal of specific lipoproteins. Thus, the efficacy of a specific drug is determined by its effect on production or removal of the lipoproteins present in excess in each type of hyperlipoproteinemia.3

Hypolipidemic drugs can control hyperlipoproteinemia by one of two

REFERENCES

Fredrickson DS, Levy RI:  Familial hyperlipoproteinemia , in Stanbury JB, Wyngaarden JB, Fredrickson DS (eds): The Metabolic Basis of Inherited Disease , ed 3. New York, McGraw-Hill Book Co Inc, 1972;, pp 545-614.
Morganroth J, Levy RI:  The diagnosis and management of the hyperlipoproteinemias , in Donoso E (ed): Drugs in Cardiology . New York, Stratton Intercontinental, 1975;, pp 127-156.
Levy RI, Morganroth J, Rifkind BM:  Drug therapy: Treatment of hyperlipidemia . N Engl J Med 290:1295-1301, 1974;.
Fredrickson DS, Levy RI, Bonnell M, et al: Dietary Management of Hyperlipoproteinemia , Dept of Health, Education, and Welfare publication No. (NIH) 75-110, 1974;.
Levy RI, Fredrickson DS, Shulman R, et al:  Dietary and drug treatment of primary hyperlipoproteinemia . Ann Intern Med 77:267-294, 1972;.
The Coronary Drug Project Research Group:  Clofibrate and niacin in coronary heart disease . JAMA 231:360-381, 1975;.
Kuo PT, Fan WC, Kostis JB, et al:  Combined para-aminosalicylic acid and dietary therapy in long-term control of hypercholesterolemia and hypertriglyceridemia (types IIa and IIb hyperlipoproteinemia) . Circulation 53:338-341, 1976;.
Levy RI, Rifkind BM:  Lipid lowering drugs and hyperlipidaemia . Drugs 6:12-45, 1973;.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Fredrickson DS, Levy RI:  Familial hyperlipoproteinemia , in Stanbury JB, Wyngaarden JB, Fredrickson DS (eds): The Metabolic Basis of Inherited Disease , ed 3. New York, McGraw-Hill Book Co Inc, 1972;, pp 545-614.
Morganroth J, Levy RI:  The diagnosis and management of the hyperlipoproteinemias , in Donoso E (ed): Drugs in Cardiology . New York, Stratton Intercontinental, 1975;, pp 127-156.
Levy RI, Morganroth J, Rifkind BM:  Drug therapy: Treatment of hyperlipidemia . N Engl J Med 290:1295-1301, 1974;.
Fredrickson DS, Levy RI, Bonnell M, et al: Dietary Management of Hyperlipoproteinemia , Dept of Health, Education, and Welfare publication No. (NIH) 75-110, 1974;.
Levy RI, Fredrickson DS, Shulman R, et al:  Dietary and drug treatment of primary hyperlipoproteinemia . Ann Intern Med 77:267-294, 1972;.
The Coronary Drug Project Research Group:  Clofibrate and niacin in coronary heart disease . JAMA 231:360-381, 1975;.
Kuo PT, Fan WC, Kostis JB, et al:  Combined para-aminosalicylic acid and dietary therapy in long-term control of hypercholesterolemia and hypertriglyceridemia (types IIa and IIb hyperlipoproteinemia) . Circulation 53:338-341, 1976;.
Levy RI, Rifkind BM:  Lipid lowering drugs and hyperlipidaemia . Drugs 6:12-45, 1973;.
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.